Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis

Golub, Lorne M.; McNamara, T. F.; Ryan, Maria Emanuel; Kohut, Bruce; Blieden, Timothy M.; Payonk, Gregory S.; Sipos, Tibor; Baron, Hazen J.

doi:10.1034/j.1600-051x.2001.028002146.x

Cited by 160 publications

(180 citation statements)

References 38 publications

(58 reference statements)

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…Therefore modulating immunoinflammatory response to the bacterial exposure is an important concept in the treatment of various inflammatory diseases including periodontal disease (27,28). Doxycycline, a member of the tetracycline family of antibiotics, has been approved by the United States Food and Drug Administration (FDA) as a host modulatory agent for use as an adjunct to conventional therapy for the treatment of chronic periodontitis 4 (7, 29,30). Approval of doxycycline, more specifically subantimicrobial dose doxycycline was based on its ability to inhibit the activity of matrix metalloproteinases (MMPs).…”

Section: Introductionmentioning

confidence: 99%

Effects of low-dose doxycycline on cytokine secretion in human monocytes stimulated with Aggregatibacter actinomycetemcomitans

et al. 2011

View full text Add to dashboard Cite

Doxycycline is an antibiotic used in the treatment of a variety of inflammatory conditions, including periodontitis. Apart from its antimicrobial properties, this drug also has independent antiinflammatory effects at sub-antimicrobial doses. The present study aimed to investigate the effects of low-doses of doxycycline (LDD) on cytokine production by human monocytic cells challenged with the periodontal pathogen Aggregatibacter actinomycetemcomitans, for up to 6h. The simultaneous regulation of 12 cytokines were measured by a Human Cytokine Array Kit. To validate the array findings, selected cytokines were also measured by enzyme-linked immunosorbant assay (ELISA). A. actinomycetemcomitans stimulated the production of tumor necrosis factor (TNF)-, interleukin (IL)-1 , IL-1 , IL-6 and IL-8 by the cells after 6h of challenge, and doxycycline significantly inhibited this effect. The kinetics of this regulation demonstrated an early (within 2h) and significant (P<0.05) inhibition of pro-inflammatory cytokines, with a mild (0.5-fold) up-regulation of the anti-inflammatory cytokine IL-10. The results indicate that LDD acts as an anti-inflammatory agent in human monocytic cells stimulated with A. actinomycetemcomitans. This model provides clear evidence that some of the clinically proven benefits of LDD may be related to its ability to regulate inflammatory mediator release by monocytic cells. This property may contribute to the clinically proven benefits of this antibiotic as an adjunctive treatment for periodontitis.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of low-dose doxycycline on cytokine secretion in human monocytes stimulated with Aggregatibacter actinomycetemcomitans

et al. 2011

View full text Add to dashboard Cite

show abstract

“…This results was agreement with the results of other studies which showed that tetracycline used in the treatment of periodontal disease have therapeutic effect unrelated to their antimicrobial activity. (16,20,39,40) Studies proposed that tetracycline, even in low dose inhibit MMPs activity and therefore, it was recommended to be used where degradation of connective tissue matrix was marked.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Systemic Delivery of Aminoguanidine Versus Doxycycline on the Resorptive Phase of Alveolar Bone Following Modified Widman Flap in Diabetic Rats : A Histopathological and Scanning Electron Microscope ( SEM ) Study

E¹,

Aldahlawi²,

El-Deeb³

et al. 2014

IJHS

View full text Add to dashboard Cite

Abstract:Objectives: Aminoguanidine (guanylhydrazinehydrochloride) is a drug that prevents many of the classical systemic complications of diabetes including diabetic osteopenia through its inhibitory activity on the accumulation of advanced glycation end -products (AGEs). The aim of the present study was to evaluate the effectiveness of aminoguanidine versus doxycycline in reducing alveolar bone resorption following mucoperiosteal flap in diabetic rats, using the conventional histopathology and scanning electron microscope (SEM).Methods: Twenty-seven male albino rats were used in this study. Periodontal defects were induced experimentally on lower anterior teeth. All rats were subjected to induction of diabetes, by IV injection of the pancreatic B-cells toxin alloxan monohydrate. After eight weeks following the establishment of periodontal defects in all rats, the ligation was removed and 3 rats were scarified as negative control (group1). The remaining animals were divided into three group based on treatment applied following mucoperiosteal flap surgery. Group 2receivedsaline treatment only, group 3 received doxycycline periostat (1.5 mg/kg/day) for 3 weeks, and group 4 received aminoguanidine (7.3 mmol/kg) for 3 weeks. The fasting glucose level was measured weekly post operatively. After 21 days all rats were sacrificed. Three anterior parts of the mandible of each group was prepared for histopathologicalexamination and two parts were prepared for SEM.Results: Aminoguanidine treated group (group4) showed statistically significant increased new bone formation, higher number of osteoblasts and decrease osteoclasts number, resorptive lacunae and existing inflammatory cell infiltration as compared to positive control group (group 2) (P<0.05). Doxycycline was also effective in reducing bone loss as documental by histopathological study. Conclusion:The present study showed that aminoguanidine was significantly effective in reducing alveolar bone loss and can modify the detrimental effects of diabetes in alveolar bone resorption.

show abstract

“…A combination of metronidazole and clindamycin for three weeks also produced improved attachment levels. (Gomi, et al, 2007, Sigusch, et al, 2001. Some data to date supports a clinical benefit from the use of azithromycin as a systemic approach in combination with mechanical routines.…”

Section: Systemic Antibioticsmentioning

confidence: 99%

“…Some data to date supports a clinical benefit from the use of azithromycin as a systemic approach in combination with mechanical routines. In one limited study, seventeen subjects receiving azithromycin (500 mg), three days before full-mouth scaling and root planing produced greater clinical improvement than in seventeen subjects treated with full-mouth scaling and root planing alone (Gomi, et al, 2007). Dastoor et al studied thirty patients who reported smoking more than one pack per day and presented with periodontitis.…”

Section: Systemic Antibioticsmentioning

confidence: 99%

Present and Future Non-Surgical Therapeutic Strategies for the Management of Periodontal Diseases

Leite¹,

Kirkwood²

2012

Periodontal Diseases - A Clinician's Guide

View full text Add to dashboard Cite

Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis

Abstract: Doxycycline administered at subantimicrobial doses led to improvements in disease parameters, with no apparent side effects, and appears to have significant potential as an oral adjunctive therapy in the long-term management of adult periodontitis.

Cited by 160 publications

References 38 publications

Effects of low-dose doxycycline on cytokine secretion in human monocytes stimulated with Aggregatibacter actinomycetemcomitans

Effects of low-dose doxycycline on cytokine secretion in human monocytes stimulated with Aggregatibacter actinomycetemcomitans

The Effect of Systemic Delivery of Aminoguanidine Versus Doxycycline on the Resorptive Phase of Alveolar Bone Following Modified Widman Flap in Diabetic Rats : A Histopathological and Scanning Electron Microscope ( SEM ) Study

Present and Future Non-Surgical Therapeutic Strategies for the Management of Periodontal Diseases

Contact Info

Product

Resources

About